News & Events

• April 14, 2022
  

  Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium

  Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.

  Dr. Rakhilin joined C-Path after working in the pharmaceutical industry for 15 years. His work focused on various aspects of drug development, from target identification to clinical studies and biomarker analysis. He has contributed to the development of several treatments for muscle atrophy, hematological, and neurodegenerative diseases.

• April 8, 2021
  

  CP-SCD Announces Pfizer Executive as its First Industry Co-Director

  C-Path’s Critical Path to Sickle Cell Disease Consortium (CP-SCD) is pleased to announce Dr. David Readett of Pfizer as its first Industry Co-Director. David is a pediatrician/pediatric hematologist/oncologist who, prior to transitioning to clinical research in the pharmaceutical industry, spent 18 years in clinical practice, with a focus on clinical care and research for pediatric...
• September 17, 2020
  

  C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease

  TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease.